Hospira – Recall of buprenorphine injection and labetalol injection

- On May 21, 2024, Hospira announced a voluntary user-level recall of two lots of buprenorphine injection and three lots of labetalol injection due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.

- The recalled products were distributed nationwide to wholesalers/hospitals from September 2023 through April 2024.

Product Description	NDC number	Lot number (Exp Date)
Buprenorphine hydrochloride injection Carpuject™ single-dose cartridge/tube unit with luer lock	Carton: 0409-2012-32 Cartridge: 0409-2012-03	HJ3965 (9/2024); HJ8546 (10/2024)
Labetalol hydrochloride injection, Carpuject™ single-dose cartridge/tube unit with luer lock	Bundle: 0409-2339-34 Carton/cartridge: 0409-2339-24	HJ7566 (5/2025); HN8747 (9/2025); HN8749 (9/2025)

- Buprenorphine injection is indicated for the management of pain requiring an opioid analgesic and for which alternate treatments are inadequate.

- Labetalol injection is indicated for control of blood pressure in severe hypertension.

- Anyone with an existing inventory of the product being recalled should discontinue use, stop distribution, and quarantine any of the recalled lots immediately.

- Contact Sedgwick (appointed company for Hospira) by phone at **1-800-805-3093** for questions regarding this recall.